NEW YORK (GenomeWeb) – MDxHealth today announced it has licensed its methylation-specific PCR technology to molecular diagnostics firm Oncgnostics for use in a cervical cancer test.
The agreement grants Jena, Germany-based Oncgnostics a limited, non-transferable, non-exclusive, worldwide license for diagnostic applications in cervical cancer.
"This technology allows for the accurate and sensitive assessment of DNA methylation markers included in our first test, GynTect, which is intended for the early detection of cervical neoplasias that may progress to cancer," Oncgnostics CEO Alfred Hansel said in a statement.
In return, MDxHealth will receive upfront and milestone payments and royalties on net sales.
"DNA methylation is a proven diagnostic tool for cancer detection," said MDxHealth CEO Jan Groen, pointing to three existing products on the market based on the firm's proprietary technology and biomarkers: its own offerings ConfirmMDx for prostate cancer and PredictMDx for glioblastoma, as well as Exact Sciences' Cologuard test for colorectal cancer screening.
Financial details were not disclosed.